[Combination of phentolamine and angelicini in cholestasis and severe type of chronic active hepatitis B].
Among 60 patients with chronic active hepatitis B, 43 were of the severe type, 17 were of cholestasis type. Each type was divided randomly into two groups: therapeutic and control. The former received both conventional supporting therapy and combination of phentolamine (20-30 mg/day) and angelicini (150-450 mg/day). The latter was only treated with conventional supporting therapy. Digital subtraction angiography (DSA) and platelet agglutination test were performed in 10 patients respectively. DSA demonstrated that liver sinusoids were expanded and the vascular bed round the sinusoids were also enlarged in diameter following instillation of phentolamine. It was also shown that angelicini could suppress the second phase of platelet agglutination. These indicated that phentolamine and angelicini could improve the liver microcirculation in different way. The incidence of survival between therapeutic and the control group was 57.14% and 31.82% respectively (P less than 0.05).
Yu
D X
DX
Institute of Liver Diseases, Tongji Medical University, Wuhan.
Li
S B
SB
D000328:Adult; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006521:Hepatitis, Chronic / Q000188:drug therapy; D006801:Humans; D008102:Liver Circulation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010646:Phentolamine / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D004365:Drugs, Chinese Herbal; D010975:Platelet Aggregation Inhibitors; D010646:Phentolamine